M1908 Tenofovir Disoproxil Fumarate (TDF) for the Treatment of HBeAg-Negative Chronic Hepatitis B: Week 72 TDF Data and Week 24 Adefovir Dipivoxil Switch Data (Study 102)

MLA

Patrick Marcellin, et al. “M1908 Tenofovir Disoproxil Fumarate (TDF) for the Treatment of HBeAg-Negative Chronic Hepatitis B: Week 72 TDF Data and Week 24 Adefovir Dipivoxil Switch Data (Study 102).” Gastroenterology, vol. 134, Apr. 2008, p. A-808. EBSCOhost, https://doi.org/10.1016/s0016-5085(08)63776-2.

APA

Patrick Marcellin, Ira M. Jacobson, Naoky Tsai, Natalie Bzowej, François Habersetzer, Hakan Senturk, Christopher D. Moyes, Gerlinde Teuber, Jeff Sorbel, Jane Anderson, Elsa Mondou, Joe Quinn, & Franck Rousseau. (2008). M1908 Tenofovir Disoproxil Fumarate (TDF) for the Treatment of HBeAg-Negative Chronic Hepatitis B: Week 72 TDF Data and Week 24 Adefovir Dipivoxil Switch Data (Study 102). Gastroenterology, 134, A-808. https://doi.org/10.1016/s0016-5085(08)63776-2

Chicago

Patrick Marcellin, Ira M. Jacobson, Naoky Tsai, Natalie Bzowej, François Habersetzer, Hakan Senturk, Christopher D. Moyes, et al. 2008. “M1908 Tenofovir Disoproxil Fumarate (TDF) for the Treatment of HBeAg-Negative Chronic Hepatitis B: Week 72 TDF Data and Week 24 Adefovir Dipivoxil Switch Data (Study 102).” Gastroenterology 134 (April): A-808. doi:10.1016/s0016-5085(08)63776-2.